scPharmaceuticals reports Q1 EPS (36c), consensus (44c)

Reports Q1 revenue $6.1M , consensus $5.98M .”During the first quarter, we sustained sales momentum. We generated FUROSCIX net revenue of $6.1M , despite seasonality resulting from patient copays resetting with the new year as well as an estimated 10% negative impact to doses filled during the quarter as a result of the widely reported Change Healthcare cyberattack,” stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals. “All of our leading indicators, including unique prescribers and in-services completed, suggest that treating providers are increasingly more comfortable prescribing FUROSCIX to their heart failure patients either pre-hospital admission or post-discharge.” “Our reported gross-to-net discount of 19% for the first quarter rose slightly from our reported GTN discount from launch through the end of 2023. Looking ahead, we continue to anticipate that the GTN discount will increase over time, possibly approaching 30-35% by the end of this year, consistent with our prior long-term guidance. Our contracting efforts with payers continue to progress.” “We believe that our current commercial trajectory, together with these long-term growth initiatives, form a solid foundation from which we can drive FUROSCIX sales growth in the years ahead,” Mr. Tucker concluded.